Orthofix Medical Inc. Reports Q2 2026 Financial Results with Revenue Growth and Increased Net Loss

Orthofix Medical Inc. reported its financial results for the second quarter of 2026, revealing net sales of $210.9 million, a 3.8% increase from $203.1 million in the same period last year. The company’s gross profit rose to $149.7 million, up 7.3% year-over-year, resulting in a gross margin of 71.0%, compared to 68.7% in the prior year. Despite the revenue growth, Orthofix recorded a net loss of $15.8 million, slightly higher than the $14.1 million loss reported in the second quarter of 2025. The loss per share for the quarter was $(0.39), compared to $(0.36) in the previous year.

In terms of operational performance, the Global Spine segment generated $173.2 million in sales, reflecting a 2.0% increase, while the Global Limb Reconstruction segment saw a more significant growth of 13.2%, reaching $37.7 million. The increase in the Limb Reconstruction segment was attributed to strong international sales and the successful launch of new products. The Therapeutic Solutions category, which includes bone growth therapies, experienced a modest growth of 2.5%, despite facing temporary challenges related to Medicare reimbursement changes.

Orthofix's financial position improved, with cash and cash equivalents increasing to $103.8 million as of June 30, 2026, compared to $82.0 million at the end of 2025. The company’s total assets rose to $873.0 million, up from $850.6 million at the end of the previous fiscal year. However, total liabilities also increased to $443.8 million, primarily due to a rise in long-term debt, which reached $221.6 million, up from $157.4 million at the end of 2025. The increase in debt was linked to the company’s $65 million Term B Loan drawn in January 2026, aimed at enhancing capital flexibility.

Strategically, Orthofix has focused on integrating its operations following the merger with SeaSpine Holdings Corporation, which has led to the discontinuation of certain product lines, including the M6 artificial discs. This decision was made to allocate resources to more profitable growth opportunities. The company also reported a significant increase in share-based compensation expenses, reflecting ongoing investments in its workforce. Looking ahead, Orthofix anticipates continued growth driven by its product portfolio and market expansion efforts, although it remains cautious about potential regulatory changes and market conditions that could impact its operations.

Overall, while Orthofix Medical Inc. has shown positive revenue growth and improved gross margins, it continues to face challenges in achieving profitability, as evidenced by its ongoing net losses. The company’s strategic focus on product innovation and market expansion will be critical in navigating these challenges and enhancing shareholder value in the future.